TY  - JOUR
AU  - Placke, Jan-Malte
AU  - Rajcsanyi, Luisa Sophie
AU  - Herbst, Rudolf
AU  - Terheyden, Patrick
AU  - Utikal, Jochen
AU  - Pföhler, Claudia
AU  - Kreuter, Alexander
AU  - Mohr, Peter
AU  - Gutzmer, Ralf
AU  - Weichenthal, Michael
AU  - Meier, Friedegund
AU  - Berking, Carola
AU  - Leiter, Ulrike
AU  - Seier, Johanna
AU  - Krefting, Frederik
AU  - Tasdogan, Alpaslan
AU  - Lodde, Georg C
AU  - Livingstone, Elisabeth
AU  - Zimmer, Lisa
AU  - Roesch, Alexander
AU  - Griewank, Klaus
AU  - Schadendorf, Dirk
AU  - Ugurel, Selma
TI  - Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation status.
JO  - Frontiers in immunology
VL  - 16
SN  - 1664-3224
CY  - Lausanne
PB  - Frontiers Media
M1  - DKFZ-2025-00478
SP  - 1536642
PY  - 2025
AB  - Modern therapeutic strategies have significantly improved the prognosis of advanced melanoma patients. Predictive factors of therapy response include serum LDH; however, predictive markers for long-term survival are currently largely lacking.Patients diagnosed with stage IV melanoma (AJCCv8) of cutaneous origin or unknown primary were identified from the prospective multicenter German Dermatologic Cooperative Oncology Group (DeCOG) skin cancer registry ADOREG. Baseline characteristics were compared between patient groups with short-term versus long-term survival. Statistical analysis included ROC analysis and multinomial regression analysis.Of 3066 stage IV melanoma patients entered into the ADOREG between 05/2014 and 06/2021, 395 were identified for this study, of whom 301 (76.2
KW  - Humans
KW  - Proto-Oncogene Proteins B-raf: genetics
KW  - Melanoma: genetics
KW  - Melanoma: mortality
KW  - Melanoma: drug therapy
KW  - Male
KW  - Brain Neoplasms: secondary
KW  - Brain Neoplasms: genetics
KW  - Brain Neoplasms: mortality
KW  - Female
KW  - Middle Aged
KW  - Aged
KW  - Mutation
KW  - Adult
KW  - Skin Neoplasms: genetics
KW  - Skin Neoplasms: mortality
KW  - Skin Neoplasms: drug therapy
KW  - Skin Neoplasms: pathology
KW  - Prognosis
KW  - Neoplasm Staging
KW  - Aged, 80 and over
KW  - Prospective Studies
KW  - Immune Checkpoint Inhibitors: therapeutic use
KW  - Biomarkers, Tumor: genetics
KW  - Registries
KW  - BRAF (Other)
KW  - brain metastases (Other)
KW  - immune checkpoint inhibitor (ICI) (Other)
KW  - long-term survival (Other)
KW  - melanoma (Other)
KW  - targeted therapy (Other)
KW  - Proto-Oncogene Proteins B-raf (NLM Chemicals)
KW  - BRAF protein, human (NLM Chemicals)
KW  - Immune Checkpoint Inhibitors (NLM Chemicals)
KW  - Biomarkers, Tumor (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40028330
C2  - pmc:PMC11868123
DO  - DOI:10.3389/fimmu.2025.1536642
UR  - https://inrepo02.dkfz.de/record/299520
ER  -